Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation

Kálmán Benke, Csaba Mátyás, Alex Ali Sayour, A. Oláh, Balázs Tamás Németh, Mihály Ruppert, G. Szabó, Gábor Kökény, Eszter Mária Horváth, István Hartyánszky, Zoltán Szabolcs, B. Merkely, T. Radovits

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.

Original languageEnglish
Article number14232
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Gemfibrozil
Heart Transplantation
Pharmacology
Reperfusion Injury
Transplants
Reperfusion
Ventricular Pressure
Oxidative Stress
Heart Failure
Body Weight
Apoptosis

ASJC Scopus subject areas

  • General

Cite this

Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation. / Benke, Kálmán; Mátyás, Csaba; Sayour, Alex Ali; Oláh, A.; Németh, Balázs Tamás; Ruppert, Mihály; Szabó, G.; Kökény, Gábor; Horváth, Eszter Mária; Hartyánszky, István; Szabolcs, Zoltán; Merkely, B.; Radovits, T.

In: Scientific Reports, Vol. 7, No. 1, 14232, 01.12.2017.

Research output: Contribution to journalArticle

Benke, K, Mátyás, C, Sayour, AA, Oláh, A, Németh, BT, Ruppert, M, Szabó, G, Kökény, G, Horváth, EM, Hartyánszky, I, Szabolcs, Z, Merkely, B & Radovits, T 2017, 'Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation', Scientific Reports, vol. 7, no. 1, 14232. https://doi.org/10.1038/s41598-017-14587-3
Benke, Kálmán ; Mátyás, Csaba ; Sayour, Alex Ali ; Oláh, A. ; Németh, Balázs Tamás ; Ruppert, Mihály ; Szabó, G. ; Kökény, Gábor ; Horváth, Eszter Mária ; Hartyánszky, István ; Szabolcs, Zoltán ; Merkely, B. ; Radovits, T. / Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{d8ed7dd3f0b24ac6ac325216a11368ae,
title = "Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation",
abstract = "While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.",
author = "K{\'a}lm{\'a}n Benke and Csaba M{\'a}ty{\'a}s and Sayour, {Alex Ali} and A. Ol{\'a}h and N{\'e}meth, {Bal{\'a}zs Tam{\'a}s} and Mih{\'a}ly Ruppert and G. Szab{\'o} and G{\'a}bor K{\"o}k{\'e}ny and Horv{\'a}th, {Eszter M{\'a}ria} and Istv{\'a}n Harty{\'a}nszky and Zolt{\'a}n Szabolcs and B. Merkely and T. Radovits",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-14587-3",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation

AU - Benke, Kálmán

AU - Mátyás, Csaba

AU - Sayour, Alex Ali

AU - Oláh, A.

AU - Németh, Balázs Tamás

AU - Ruppert, Mihály

AU - Szabó, G.

AU - Kökény, Gábor

AU - Horváth, Eszter Mária

AU - Hartyánszky, István

AU - Szabolcs, Zoltán

AU - Merkely, B.

AU - Radovits, T.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.

AB - While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.

UR - http://www.scopus.com/inward/record.url?scp=85032463933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032463933&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-14587-3

DO - 10.1038/s41598-017-14587-3

M3 - Article

AN - SCOPUS:85032463933

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 14232

ER -